The estimated Net Worth of Christian Klemt is at least $3.49 million dollars as of 17 June 2024. Mr Klemt owns over 1,611 units of uniQure N.V stock worth over $901,658 and over the last 7 years he sold QURE stock worth over $2,197,036. In addition, he makes $392,598 as CFO et Principal Financial Officer & GM of Amsterdam Site at uniQure N.V.
Mr has made over 19 trades of the uniQure N.V stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 1,611 units of QURE stock worth $7,733 on 17 June 2024.
The largest trade he's ever made was selling 15,906 units of uniQure N.V stock on 26 February 2024 worth over $101,480. On average, Mr trades about 3,213 units every 76 days since 2017. As of 17 June 2024 he still owns at least 164,837 units of uniQure N.V stock.
You can see the complete history of Mr Klemt stock trades at the bottom of the page.
Christian Klemt is the CFO, Principal Financial Officer & GM of Amsterdam Site at uniQure N.V.
As the CFO et Principal Financial Officer & GM of Amsterdam Site of uniQure N.V, the total compensation of Mr Klemt at uniQure N.V is $392,598. There are 7 executives at uniQure N.V getting paid more, with Matthew Kapusta having the highest compensation of $4,719,960.
Mr Klemt is 48, he's been the CFO et Principal Financial Officer & GM of Amsterdam Site of uniQure N.V since . There are 14 older and 1 younger executives at uniQure N.V. The oldest executive at uniQure N.V. is Jack Kaye, 76, who is the Non-Executive Independent Director.
Christian's mailing address filed with the SEC is C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, P7, 11058BP.
Over the last 8 years, insiders at uniQure N.V have traded over $35,572,573 worth of uniQure N.V stock. The most active insiders traders include Deventer Sander Van, Paula Soteropoulos et William Lewis. On average, uniQure N.V executives and independent directors trade stock every 14 days with the average trade being worth of $37,634. The most recent stock trade was executed by Walid Abi Saab on 26 June 2024, trading 1,447 units of QURE stock currently worth $6,309.
uniqure is delivering on the promise of gene therapy - single treatments with potentially curative results. we are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with severe genetic diseases.
uniQure N.V executives and other stock owners filed with the SEC include: